Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.


About Us

Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.  

The basis of Laxxon’s pharmaceutical solutions is our cutting-edge 3D screen printing technology and the extensive intellectual property surrounding it. 

Our commitment to innovation and health is fueled by the expertise, integrity, agility and diversity of the Laxxon team. 

Laxxon Medical was founded in 2017. We hold the exclusive worldwide rights to the patented use and application of SPID® (Screen Printed Innovative Drug) Technology for the development, manufacture and commercialization of pharmaceutical dosage forms. 

Vast End Market Opportunity

More than 150 drugs patent protections expire within the next 10 years, amounting to a total value of $190 billion in sales.

Laxxon offers three disruptive avenues for strategic opportunities within the pharmaceutical industry: Advanced Patented Generics, Patent Extension through Technology Transfer, and New Drug Development. 

Pipeline & Partners

Our extensive pipeline features 12 in-house development programs. We are actively running 6 of these 12 programs. Additionally we have three contractual development programs with external industrial partners. 

 

Our Team

 
IMG_5708_edited_edited_edited.jpg

Helmut Kerschbaumer

CEO/Chairman of the Board

Helmut Kerschbaumer trained in distribution with German C&A and joined the management board of the company (Austria). After 15 years in the retail industry, Helmut was appointed as Managing Director of Melbrosin International, an international pharmaceutical distributor, which he took over in a management buyout in 2000 and later successfully sold to Bioprogress Plc, UK. Helmut spent 2 years as Director at a UK listed pharmaceutical company. Between 2012 and 2016, Helmut was the CEO of IPMD GmbH and between 2013 and 2017 director and CEO at Uluru Inc., USA.

Contact Us

Thanks for submitting!

IMG_20211101_084043_edited.jpg